-
Morning Market Movers (GMCR, ATRN, HGSI, XRM)
Thursday, March 10, 2011 - 10:47am | 191Green Mountain Coffee Roasters Inc (NASDAQ: GMCR) shares surged 30.42% to $56.92 at 9:45 am. GMCR agreed to sell Starbucks Corp's (NASDAQ: SBUX) coffee and Tazo teas pods for its popular Keurig machines. Atrinsic Inc (NASDAQ: ATRN) climbed 19.91% to $5.06. ATRN reported that subscribers to its...
-
Piper Jaffray Reduces Corcept Therapeutics PT From $7.40 (CORT)
Thursday, March 10, 2011 - 10:23am | 140Piper Jaffray reduced its Corcept Therapeutics (NASDAQ: CORT) price target from $7.40 to $6 in a research report published today. Piper Jaffray made no change to its Corcept Therapeutics Overweight rating. In the report, Piper Jaffray states, "Corcept ended 2010 with $24.6mn and, with the recent...
-
Jefferies Lowers POZN Target From $7 To $5
Thursday, March 10, 2011 - 10:06am | 30Jefferies is lowering its PT on shares of POZEN, Inc. (NASDAQ: POZN) from $7 to $5. POZEN closed Wednesday at $4.96.
-
Benzinga's Top Pre-Market NASDAQ Gainers (GMCR, HGSI, SBUX, ATRN)
Thursday, March 10, 2011 - 9:24am | 193Green Mountain Coffee Roasters Inc (NASDAQ: GMCR) rose 29.93% to $56.70 in the pre-market session. GMCR agreed to sell Starbucks Corp's (NASDAQ: SBUX) coffee and Tazo teas pods for its popular Keurig machines. Human Genome Sciences Inc (NASDAQ: HGSI) added 8.41% to $27.84 in the pre-market session...
-
CoreSite Reports Results for the Fourth Quarter 2010
Thursday, March 10, 2011 - 8:32am | 122CoreSite Realty Corporation (NYSE: COR), a national provider of powerful, network-rich data centers, today announced financial results for the fourth quarter 2010. Highlights: Reported FFO of $0.25 per diluted share for the quarter ended December 31, 2010 Signed 33,135 NRSF of new and expansion...
-
Spectrum Pharmaceuticals Announces 4Q EPS of $0.08 vs. ($0.05)
Thursday, March 10, 2011 - 8:22am | 20Spectrum Pharmaceuticals (NASDAQ: SPPI) announced its 4Q EPS of $0.08 vs. ($0.05).
-
One Side of Market May Tip Hand 03-09-11
Wednesday, March 9, 2011 - 7:06pm | 778Cusick's Corner Timing is everything, but so is patience. For a lot of traders and investors patience is being tested. The critical point at this juncture is not to overreact or over trade. This is easy to type but sometimes not easy to follow. Especially when we see things like today's decent 10...
-
Human Genome Wins Approval For Benlysta (HGSI)
Wednesday, March 9, 2011 - 6:26pm | 55Human Genome (NASDAQ: HGSI) has received approval from the FDA for its lupus drug Benlysta, which is co-marketed with Glaxoo Smith Kline (NYSE: GSK). Shares of Human Genome are trading at $25.55, and is still halted.
-
Bristol-Myers Squibb to Present at Barclays Capital Global Healthcare Conference
Wednesday, March 9, 2011 - 11:02am | 48Bristol-Myers Squibb Company (NYSE: BMY) will present at Barclays Capital 2011 Healthcare Conference on Wednesday, March 16, 2011, in Miami. Renzo Canetta, vice president, Oncology Global Clinical Research, will make a formal presentation about the company at 3:45 p.m. EST.
-
(ALI) To Get Up From A Punch?
Wednesday, March 9, 2011 - 10:31am | 794Ayala Land, Inc. (ALI) suddenly showed some signs of life earlier today when it beat the 8 count and closed at PHP 15.28. Not only did it barely ended just outside the resistance of a descending channel, it also attempted to break out from a small inverted head and shoulders...
-
Goldman Sachs Maintains Buy on Mylan Inc. (MYL)
Wednesday, March 9, 2011 - 10:08am | 95Goldman Sachs is out with its report this morning on Mylan Inc. (NASDAQ: MYL), maintaining Buy after meeting with management. In a note to clients, Goldman Sachs writes, "Near-term path remains attractive with 1Q a low hurdle in our view and a more active launch pipeline in 2011 likely to instill...
-
Oppenheimer Reports On Strong 4Q For Simcere Pharmaceutical Group
Wednesday, March 9, 2011 - 10:08am | 157In a report published Oppenheimer, Simcere Pharmaceutical Group (NYSE: SCR) saw a strong 4Q, and growing domestic market and sales investment could lead to upside. Oppenheimer said that SCR's 4Q was strong, with EPS of $0.16 significantly exceeding Street's consensus of $0.09, driven by a handsome...
-
Goldman Sachs Comments On Warner Chilcott (WCRX)
Wednesday, March 9, 2011 - 9:59am | 159Goldman Sachs provided color on Warner Chilcott (NASDAQ: WCRX) in a research report published today. In the report, Goldman Sachs states, "After the close on March 8, Warner Chilcott (WCRX) announced a secondary offering of 25 million shares (plus 15% greenshoe provision) as part of a further...
-
KineMed Extends Collaboration With Bristol-Myers Squibb
Wednesday, March 9, 2011 - 9:14am | 60KineMed, Inc. announced today the extension of its collaboration with Bristol-Myers Squibb (NYSE: BMY) in the area of Alzheimer's disease and other neurodegenerative conditions. Under the terms of the extension, Bristol-Myers Squibb has non-exclusively licensed KineMed's technologies to identify...
-
ViroPharma To Repurchase Up To $150 Million Worth Of Shares
Wednesday, March 9, 2011 - 8:36am | 44ViroPharma Incorporated (NASDAQ: VPHM) today announced that the company's Board of Directors has authorized the use of up to $150 million to repurchase shares of its common stock and/or its 2% Senior Convertible Notes due 2017.